IP Library Patent Application 13902941
Patent Application
App. No. 13/902,941

METHODS AND COMPOSITIONS FOR THE REDUCTION OF NEUTROPHIL INFLUX AND THE TREATMENT OF BRONCHOPULMONARY DISPLASIA, RESPIRATORY DISTRESS SYNDROME, CHRONIC LUNG DISEASE, PULMONARY FIBROSIS, ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/902,941
Abstract

The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of Respiratory Distress Syndrome (RDS), Bronchopulmonary dysplasia (BPD), chronic lung disease and/or pulmonary fibrosis, Asthma and Chronic Obstructive Pulmonary Disease (COPD). More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10, which may be administered to safely and effectively treat the aforementioned conditions. The invention further provides a composition useful in administering rhCC10 to humans.

Claims (2)

1 . A method of treatment of a patient having respiratory distress syndrome, bronchopulmonary dysplasia, chronic lung disease, pulmonary fibrosis, asthma or chronic obstructive pulmonary disease and in need of treatment, comprising: administering a treatment-effective amount of rhCC10 to said patient.

2 - 37 . (canceled)

Assignments (2)
CHANGE OF NAME Recorded Apr 3, 2015
From: CLARASSANCE INC.
To: THERABRON THERAPEUTICS INC.
Reel/Frame 035365/0889 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2014
From: PILON-CLAYTON, APRILE L
To: CLARASSANCE, INC.
Reel/Frame 032960/0370 →